Form 4: Rocket Pharmaceuticals CEO Gaurav Shah Increases Stake in Company
SEC Form 4
CEO Gaurav Shah recently purchased 20,000 shares of Rocket Pharmaceuticals at $5.08 per share, increasing his direct holdings.
Summary
- Gaurav Shah, CEO of Rocket Pharmaceuticals, acquired 20,000 shares of common stock on April 10, 2025, at a price of $5.08 per share.
- Following this transaction, Shah directly owns 792,680 shares of Rocket Pharmaceuticals.
- Shah also has indirect ownership through his spouse (207,897 shares) and the Gaurav D. Shah Irrevocable Trust (198,341 shares).
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which can be interpreted as a sign of confidence. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase positively.
Key Dates
| Date | Description |
|---|---|
| 04/10/2025 | Date of the transaction where Gaurav Shah acquired 20,000 shares of common stock. |
| 04/14/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
Rocket Pharmaceuticals, Gaurav Shah, stock purchase, beneficial ownership, RCKT, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.